Phio Pharmaceuticals Corp. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to offer and sell up to $6,360,000 of common stock from time to time.
Key takeaways
Entered Sales Agreement with H.C. Wainwright & Co., LLC on April 8, 2026 for ATM sales of up to $6.36M in Shares.
Sales Agent receives 3.0% commission on gross proceeds from Share sales.
Offering registered under Form S-3 (File No. 333-279557), effective July 1, 2024.
Company controls sales parameters including volume, timing, and minimum price.
No obligation to sell Shares; can suspend or terminate agreement at any time.
Legal opinion from Hogan Lovells US LLP confirms Shares will be validly issued, fully paid, nonassessable.